Oak Hill Bio

Oak Hill Bio company information, Employees & Contact Information

Explore related pages

Related company profiles:

Oak Hill Bio is a clinical-stage biotech company committed to developing life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases.

Company Details

Employees
24
Address
The Underlying Disease Biology Of #angelmansyndrome
Industry
Biotechnology
Looking for a particular Oak Hill Bio employee's phone or email?

Oak Hill Bio Questions

News

Oak Hill Bio Announces Publication of Rugonersen Phase 1 Study Results in Nature Medicine - Yahoo Finance

Oak Hill Bio Announces Publication of Rugonersen Phase 1 Study Results in Nature Medicine Yahoo Finance

Oak Hill Bio Enters into Exclusive License Agreement with Roche to Obtain Global Rights for a Phase 3-Ready, Potential Best-in-Class Treatment for Individuals with Angelman Syndrome - Business Wire

Oak Hill Bio Enters into Exclusive License Agreement with Roche to Obtain Global Rights for a Phase 3-Ready, Potential Best-in-Class Treatment for Individuals with Angelman Syndrome Business Wire

Oak Hill Bio Spotlights Publication Detailing Discovery and Initial Development of Rugonersen in Nucleic Acids Research - Lelezard

Oak Hill Bio Spotlights Publication Detailing Discovery and Initial Development of Rugonersen in Nucleic Acids Research Lelezard

Oak Hill Bio Promotes Josh Distler To CEO - citybiz

Oak Hill Bio Promotes Josh Distler To CEO citybiz

Oak Hill Bio Acquires Roche’s Angelman Drug and Plans Phase III - Inside Precision Medicine

Oak Hill Bio Acquires Roche’s Angelman Drug and Plans Phase III Inside Precision Medicine

Oak Hill Bio - The Pharma Letter

Oak Hill Bio The Pharma Letter

Takeda Births Oak Hill Bio to Solve Rare Autoimmune Diseases - BioSpace

Takeda Births Oak Hill Bio to Solve Rare Autoimmune Diseases BioSpace

Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy - Business Wire

Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy Business Wire

Takeda Spins Off Rare Disease Therapeutics Company Oak Hill Bio - Inside Precision Medicine

Takeda Spins Off Rare Disease Therapeutics Company Oak Hill Bio Inside Precision Medicine

Oak Hill Bio Launches With Pipeline and Senior Leadership From Takeda - Business Wire

Oak Hill Bio Launches With Pipeline and Senior Leadership From Takeda Business Wire

Top Oak Hill Bio Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant